由EBF1诱导的CSRP2通过抑制铁化促进B细胞急性淋巴细胞白血病的进展,从而抑制B细胞急性淋巴细胞白血病的进展
Chengcheng Liu1, Gexiu Liu2, Fenling Zhou3
1Department of Hematology, The Third Affiliated Hospital of Sun Yat-Sen University, Sun Yat-Sen Institute of Hematology, Guangzhou, Guangdong, 510630, PR China.
Cancer letters
|February 14, 2025
概括
富含氨酸和甘氨酸的蛋白2 (CSRP2) 在B细胞急性淋巴细胞白血病 (B-ALL) 中被上调,导致癌症的进展. 针对EBF1/CSRP2通路可能提供新的B-ALL治疗方法.
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 分子生物学分子生物学
背景情况:
- B细胞急性淋巴细胞白血病 (B-ALL) 是一种具有不良患者结局的侵袭性癌症.
- 对于早期B-ALL干预的新型诊断标记物和治疗点的需求非常严重.
研究的目的:
- 为了确定新的分子标记物和B-ALL的治疗点.
- 研究囊蛋白和富含甘氨酸的蛋白2 (CSRP2) 在B-ALL病变发生过程中的作用.
主要方法:
- 在B-ALL患者和健康捐赠者的骨髓样本上进行了下一代RNA测序.
- 使用功能性测试来评估CSRP2和EBF1调节对B-ALL细胞的影响.
- 机制研究探讨了EBF1和CSRP2之间的监管关系.
主要成果:
- 发现囊蛋白和富含甘氨酸的蛋白2 (CSRP2) 在B-ALL中被上调.
- 下调CSRP2抑制了B-ALL细胞的增殖,并增强了细胞亡.
- 抑制CSRP2增加了B-ALL细胞中的铁亡.
- 转录因子早期B细胞因子1 (EBF1) 被确定为B-ALL.中CSRP2水平的调节者.
结论:
- EBF1/CSRP2轴的调节失调有助于B-ALL的进展.
- EBF1/CSRP2通路代表了对B-ALL治疗的有前途的治疗标.
相关概念视频
01:01Regulation of Hematopoietic Stem Cells
3.1K
All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...
3.1K
02:26NF-κB-dependent Signaling Pathway
7.2K
The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The...
NF-κB-dependent Signaling Mechanism
The...
7.2K